
    
      Objectives

        1. To assess the safety, tolerability and initial anti-diabetic activity of MLR-1023 in
           subjects with uncontrolled mild to moderate type 2 diabetes mellitus

        2. To evaluate the pharmacokinetics of MLR-1023 and the major metabolite, MLR-1023-M1
           following 28 days of repeat dosing

      Design and Outcomes

      The study is a randomized, double blind, placebo-controlled, parallel group study of MLR-1023
      in adult subjects with uncontrolled type 2 diabetes mellitus who are on diet and exercise
      therapy.

      A subset of subjects per dose group will have additional samples analyzed to measure signs of
      MLR-1023.
    
  